Gunnar Cario

Kiel, SH, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 147 publications

Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome.

Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome.

Journal: Leukemia
Published: April 03, 2026

Measurable Residual Disease-Dependent Unfavorable Outcomes in Pediatric PAX5-Rearranged B-Acute Lymphoblastic Leukemia.

Measurable Residual Disease-Dependent Unfavorable Outcomes in Pediatric PAX5-Rearranged B-Acute Lymphoblastic Leukemia.

Journal: Blood
Published: February 13, 2026

clinTALL: machine learning-driven multimodal subtype classification and treatment outcome prediction in pediatric T-ALL.

clinTALL: machine learning-driven multimodal subtype classification and treatment outcome prediction in pediatric T-ALL.

Journal: Genome medicine
Published: December 22, 2025

Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.

Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 10, 2025

KMT2A-rearranged B-lymphoblastic lymphomas are skewed towards a more mature developmental stage.

KMT2A-rearranged B-lymphoblastic lymphomas are skewed towards a more mature developmental stage.

Journal: Leukemia
Published: October 22, 2025

Philadelphia chromosome-positive acute lymphoblastic leukaemia in children and adolescents: A changing treatment landscape and a methodological challenge.

Philadelphia chromosome-positive acute lymphoblastic leukaemia in children and adolescents: A changing treatment landscape and a methodological challenge.

Journal: British journal of haematology
Published: September 17, 2025

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Journal: HemaSphere
Published: September 09, 2025

Biological and clinical characteristics of ETV6::RUNX1-like ALL.

Biological and clinical characteristics of ETV6::RUNX1-like ALL.

Journal: HemaSphere
Published: August 28, 2025

Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups.

Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups.

Journal: HemaSphere
Published: August 14, 2025

Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapy.

Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapy.

Journal: HemaSphere
Published: May 27, 2025

Epidemiology, survival, and treatment of acute myeloid and lymphoblastic leukaemia in Germany: a nationwide population-based registry analysis.

Epidemiology, survival, and treatment of acute myeloid and lymphoblastic leukaemia in Germany: a nationwide population-based registry analysis.

Journal: The Lancet regional health. Europe
Published: May 18, 2025

Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax.

Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax.

Journal: Leukemia
Published: December 02, 2024
Showing 1-12 of 147

Last Updated: 09/26/2026